Literature DB >> 11878658

Xenon produces minimal haemodynamic effects in rabbits with chronically compromised left ventricular function.

B Preckel1, W Schlack, T Heibel, H Rütten.   

Abstract

BACKGROUND: Xenon has only minimal haemodynamic side-effects on normal myocardium and might be a preferable anaesthetic agent for patients with heart failure. We studied the haemodynamic changes caused by 70% xenon in rabbits with chronically compromised left ventricular (LV) function.
METHODS: Anaesthetized rabbits were thoracotomized and a major coronary artery was ligated to induce ischaemic heart disease. Nine weeks later, rabbits were again anaesthetized (ketamine/propofol), and haemodynamics were measured during inhalation of 70% xenon using echocardiography [LV end-diastolic dimension (LVedD), fractional shortening (FS), velocity of circumferential fibre shortening (VcF), ejection fraction (EF)] in closed-chest animals. Subsequently, rabbits were thoracotomized and instrumented for measurement of LV pressure (tip manometer), LV dP/dtmax and cardiac output (ultrasonic flow probe). Haemodynamics were recorded again during inhalation of 70% xenon.
RESULTS: All rabbits had compromised LV function 9 weeks after coronary artery ligation. Mean LVedD increased from 12.9 (SD 0.9) mm to 17.1 (0.4) mm; EF decreased from 73 (9) to 64 (8)%; FS decreased from 36 (7) to 29 (5)%; VcF decreased from 28.9 (6.8) to 17.6 (4.7) mm s(-1); all P<0.05. Inhalation of 70% xenon had no effect on haemodynamics in closed-chest rabbits, as measured by echocardiography. After invasive instrumentation, small decreases in LV pressure from 78 (20) to 72 (19) mm Hg, LV dP/dtmax from 3081 (592) to 2633 (503) mm Hg s(-1) and cardiac output from 239 (69) to 225 (71) ml min(-1) were observed during xenon inhalation (all P<0.05).
CONCLUSION: These data show that xenon has only minimal negative inotropic effects in rabbits with LV dysfunction after coronary artery ligation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11878658     DOI: 10.1093/bja/88.2.264

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  11 in total

1.  Magnetic resonance imaging (MRI) assessment of ventricular remodeling after myocardial infarction in rabbits.

Authors:  Filip Konecny
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

Review 2.  Noble gases as cardioprotectants - translatability and mechanism.

Authors:  Kirsten F Smit; Nina C Weber; Markus W Hollmann; Benedikt Preckel
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

3.  Mechanisms of xenon- and isoflurane-induced preconditioning - a potential link to the cytoskeleton via the MAPKAPK-2/HSP27 pathway.

Authors:  Nina C Weber; Octavian Toma; Jessica I Wolter; Nicole M Wirthle; Wolfgang Schlack; Benedikt Preckel
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

4.  Telemetric left ventricular monitoring using wireless telemetry in the rabbit model.

Authors:  Mallory K Tate; William S Lawrence; Randy L Gourley; Diana L Zavala; Lori E Weaver; Scott T Moen; Johnny W Peterson
Journal:  BMC Res Notes       Date:  2011-09-05

Review 5.  Which neuroprotective agents are ready for bench to bedside translation in the newborn infant?

Authors:  Nicola J Robertson; Sidhartha Tan; Floris Groenendaal; Frank van Bel; Sandra E Juul; Laura Bennet; Matthew Derrick; Stephen A Back; Raul Chavez Valdez; Frances Northington; Alistair Jan Gunn; Carina Mallard
Journal:  J Pediatr       Date:  2012-02-09       Impact factor: 4.406

6.  The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKC-epsilon and p38 MAPK.

Authors:  Nina C Weber; Octavian Toma; Jessica I Wolter; Detlef Obal; Jost Müllenheim; Benedikt Preckel; Wolfgang Schlack
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

7.  Xenon preconditioning: the role of prosurvival signaling, mitochondrial permeability transition and bioenergetics in rats.

Authors:  Yasushi Mio; Yon Hee Shim; Ebony Richards; Zeljko J Bosnjak; Paul S Pagel; Martin Bienengraeber
Journal:  Anesth Analg       Date:  2009-03       Impact factor: 5.108

8.  Safety and feasibility of xenon as an adjuvant to sevoflurane anaesthesia in children undergoing interventional or diagnostic cardiac catheterization: study protocol for a randomised controlled trial.

Authors:  Sarah Devroe; Jurgen Lemiere; Marc Van de Velde; Marc Gewillig; Derize Boshoff; Steffen Rex
Journal:  Trials       Date:  2015-03-04       Impact factor: 2.279

9.  Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application.

Authors:  Xue Xia; Joseph P Babcock; Sachiko I Blaber; Kathleen M Harper; Michael Blaber
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

10.  XENON in medical area: emphasis on neuroprotection in hypoxia and anesthesia.

Authors:  Ecem Esencan; Simge Yuksel; Yusuf Berk Tosun; Alexander Robinot; Ihsan Solaroglu; John H Zhang
Journal:  Med Gas Res       Date:  2013-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.